| slide 1 of 25 september 2007 training workshop on pharmaceutical development with focus on...

| Slide 1 of 25 September 2007

Training Workshop on Pharmaceutical Development

with focus on Paediatric Formulations

Tallink City Hotel

Tallinn, Estonia

Date: 15 to 19 September 2007

Pharmaceutical DevelopmentPharmaceutical Development



Introduction to the course

Presenter: Dr Lembit Rägo

Coordinator, Quality Assurance and Safety: Medicines (QSM)

Medicines Policy and Standards (PSM)

World Health Organization

Geneva, Switzereland

E-mail: [email protected]


The need for paediatric medicines: WHO perspective

The need for paediatric medicines: WHO perspective

Background

What is a problem?

Essential medicines and paediatric dosage forms

What is WHO doing and planning to do?


Health in the Millenium Development GoalsHealth in the Millenium Development Goals

Goal 4: Reduce child mortality

Target 5 - Reduce by two-thirds, between 1990 and 2015, the under-five mortality rate

Indicators: – 13.Under-five mortality rate– 14. Infant mortality rate– 15. Proportion of one-year-old children immunized against

measles


Background Background

Likely most of the medicines in paediatric practice used Globally

– Do not have "paediatric indication" approved by regulators– Are used as "Off label" – Lack proper paediatric formulations

XXI Century with all its technology achievements has given little to children

– How long will children remain a "neglected population"?


BackgroundBackground

Why approved by regulators paediatric indications are important?

– Mostly gives assurance that the indication is based on evidence i.e. based on clinical research in respective paediatric age group(s)

– Makes it possible for generic manufacturers to refer to originators indication



Why many medicines lack paediatric indications?– Research in paediatric populations more complicated and,

perhaps, more costly– Paediatric population is not ONE, but several depending on the

age group– May not necessarily be commercially attractive– Problem ignored as kids perceived as small adults (thus, no

need for specific research and development) – History of art example



Why different from adults?– Pharmacokinetics may be different– Pharmacodynamics may be different– Profile of toxicity and adverse reactions may differ– Need for different, suitable for children,

pharmaceutical forms– …


What is the problem?What is the problem?

It is estimated that 10.6 million children under five die every year, many from treatable conditions

Children suffer from the same illnesses as adults but they may be more seriously affected, particularily in developing world, by certain conditions

– Respiratory tract infections– Malaria– Diarrhoeal diseases

In 2005, 2.3 million children under 15 years were HIV positive, 700 000 new cases had occurred over the 12 months


Mortality and children: Global pictureMortality and children: Global picture



Lack of paediatric indications– Not all essential medicines have paediatric indications– Some antiretrovirals do not have paediatric indications or have only for

some age groups – difficulties in dosing combination therapies

Lack of paediatric formulations– Dosing difficulties– Paediatric FDCs needed for HIV/AIDS and malaria, also TB– Can have dramatic consequences

• Example: International public health treatment program used for children big chewable tablet which caused in some cases chocking – more than 10 children died from asphyxia as no qualified help was available in the field. Death was avoidable if proper pharmaceutical form had been used …but cost and easiness of use considerations may take over



Paediatric formulations, even if existing – May not be optimal – May have problems from supply management point of view

• Large volumes if liquids/syrups• Stability problems with syrups

Paediatric formulations usually of much higher price– In average three times more expensive– Higher price limits accessability, and stimulates use of adult formulations


What WHO is doing?What WHO is doing?

Recently (2006) paediatric medicines was made one of the priorities of the WHO medicines work

– Create a "WHO Paediatric Model List of Essential Medicines" and "WHO Paediatric Model Formulary"

– Form a sub-committee of the respective WHO Expert Committee to facilitate work on paediatric medicines

– Update WHO treatment guidelines to incorporate latest paediatric evidence and dosing information

– Promote appropriate development of paediatric formulations and upon need develop pharmaceutical quality control specifications

– Intensify work on pharmacovigilance of paediatric medicines– Give paediatric medicines priority in Prequalification Programme– Consider giving additional regulatory advise and training in order to facilitate

development and regulatory approval of paediatric medicines


Recent eventsRecent events


World Health Assembly Resolution WHA60.20 (May 2007) – (1)


Member States are urged: – (1) to take steps to identify appropriate dosage forms and strengths of medicines

for children, and to encourage their manufacture and licensing– (2) to investigate whether currently available medicines could be formulated to

make them suitable for use in children; – (3) to conduct surveillance of antimicrobial resistance of locally available and

commonly prescribed medicines for children; – (4) to encourage research and development of appropriate medicines for

diseases that affect children, and to ensure that high-quality clinical trials for these medicines are conducted in an ethical manner;

– (5) to facilitate timely licensing of appropriate, high-quality and affordable medicines for children and innovative methods for monitoring the safety of such medicines, and to encourage the marketing of adequate paediatric formulations together with newly developed medicines;




Member states are urged (cont.)– (6) to promote access to essential medicines for children through inclusion, as

appropriate, of those medicines in national medicine lists, and procurement and reimbursement schemes, and to devise measures to monitor prices;

– (7) to collaborate in order to facilitate innovative research and development on, formulation of, regulatory approval of, provision of adequate prompt information on, and rational use of, paediatric medicines and medicines authorized for adults but not approved for use in children;

– (8) to use all necessary administrative and legislative means including, where appropriate, the provisions contained in international agreements, including the agreement on Trade-Related Aspects of Intellectual Property Rights, in order to promote access to essential medicines for children.




WHA60.20 requested WHO Director-General: – (1) to promote the development, harmonization and use of standards for

clinical trials of medicines for children; to revise and regularly update the Model List of Essential Medicines in order to include missing essential medicines for children, using evidence-based clinical guidelines; and to promote application of such guidelines by Member States and international financing bodies, with initial focus on treatments for HIV/AIDS, tuberculosis, malaria and chronic diseases;

– (2) to ensure that all relevant WHO programmes, including but not limited to that on essential medicines, contribute to making safe and effective medicines as widely available for children as for adults;

– (3) to promote the development of international norms and standards for quality and safety of formulations for children, and of the regulatory capacity to apply them;




WHA60.20 requested WHO Director-General (cont.):– (4) to make available evidence-based treatment guidelines and independent

information on dosage and safety aspects of essential medicines for children, progressively to cover all medicines for children, and to work with Member States in order to implement such guidelines;

– (5) to collaborate with governments, other organizations of the United Nations system, including World Trade Organization (WTO) and World Intellectual Property Organization (WIPO), donor agencies, nongovernmental organizations and the pharmaceutical industry in order to encourage fair trade in safe and effective medicines for children and adequate financing for securing better access to medicines for children;

– (6) to report to the Sixty-second World Health Assembly, and subsequently as appropriate, through the Executive Board, on progress achieved, problems encountered and specific actions needed to further promote better access to medicines for children.


Training Workshop on Pharmaceutical Development

with focus on Paediatric Formulations

Tallink City Hotel

Tallinn, Estonia

Date: 15 to 19 September 2007



Promoting Safety of Medicines for ChildrenWHO, 2007 (pp 1- 60)

Promoting Safety of Medicines for ChildrenWHO, 2007 (pp 1- 60)

Text on the web as follows: www.who.int/entity/medicines/publications/essentialmedicines/Promotion_safe_med_childrens.pdf

WHO Book Shop for orders: http://www.who.int/bookorders/anglais/detart1.jsp?sesslan=1&codlan=1&codcol=15&codcch=705


Several further publications in journals planned on medicines for children

Several further publications in journals planned on medicines for children


New guidance to be developedNew guidance to be developed

Draft points to consider document about developing paediatric formulations under development

Additional guidance on paediatric fixed dose combinations considered

– WHO has specific guidelines for fixed dose combination drugs that have been adopted by the Expert Committee on Specifications for Pharmaceutical Preparations

– Guidelines for registration of fixed-dose combination medicinal products, WHO Technical Report Series No 929, Annex 5, Geneva 2005 (pp 94-142)

– http://www.who.int/prequal/info_applicants/Guidelines/info_for_applicants_guidelines_fdcs.htm


What will happen next?What will happen next?

Many of the mentioned activities now developing, some completed

The Expert Committee on Selection and Use of Essential Medicines will discuss and approve the paediatric subcommittee work – 1st Model List for Essential Medicine for Children

Web site for information:

http://www.who.int/medicines/areas/rational_use/en/index.html

Better medicines for children will be a topic for the upcoming 13th ICDRA in Bern 16 -19 September 2008 – two days pre-meeting planned during 14-15 September 2008

– Web site: http://www.who.int/medicines/icdra/en/– Special web for 13th ICDRA will come up soon: http://www.icdra.ch


Instead of conclusionsInstead of conclusions

Many thanks to those who helped us to make this course happen

– All respected individuals who contributed with their time, knowledge, enthusiasm and energy to make this training course to happen

– FIP (Industrial Section)– Ministry of Social Affairs and State Agency of

Medicines (Estonia)


Instead conclusionsInstead conclusions

Need to replicate the course exists – next likely in India

Feedback and suggestions from the resource persons and audience welcome to improve the course

Help us to improve the course!


ConclusionConclusion

Only with the help of ALL stakeholders we can achieve

BETTER MEDICINES FOR CHILDREN

| slide 1 of 25 september 2007 training workshop on pharmaceutical development with focus on...

Documents